These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 23044248)

  • 1. Cancer syndromes and therapy by stop-codon readthrough.
    Bordeira-Carriço R; Pêgo AP; Santos M; Oliveira C
    Trends Mol Med; 2012 Nov; 18(11):667-78. PubMed ID: 23044248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sense from nonsense: therapies for premature stop codon diseases.
    Bidou L; Allamand V; Rousset JP; Namy O
    Trends Mol Med; 2012 Nov; 18(11):679-88. PubMed ID: 23083810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequence specificity of aminoglycoside-induced stop condon readthrough: potential implications for treatment of Duchenne muscular dystrophy.
    Howard MT; Shirts BH; Petros LM; Flanigan KM; Gesteland RF; Atkins JF
    Ann Neurol; 2000 Aug; 48(2):164-9. PubMed ID: 10939566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Readthrough of dystrophin stop codon mutations induced by aminoglycosides.
    Howard MT; Anderson CB; Fass U; Khatri S; Gesteland RF; Atkins JF; Flanigan KM
    Ann Neurol; 2004 Mar; 55(3):422-6. PubMed ID: 14991821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceutical therapies to recode nonsense mutations in inherited diseases.
    Lee HL; Dougherty JP
    Pharmacol Ther; 2012 Nov; 136(2):227-66. PubMed ID: 22820013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of new-generation aminoglycoside promoting premature termination codon readthrough in cancer cells.
    Bidou L; Bugaud O; Belakhov V; Baasov T; Namy O
    RNA Biol; 2017 Mar; 14(3):378-388. PubMed ID: 28145797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum starvation enhances nonsense mutation readthrough.
    Wittenstein A; Caspi M; David Y; Shorer Y; Nadar-Ponniah PT; Rosin-Arbesfeld R
    J Mol Med (Berl); 2019 Dec; 97(12):1695-1710. PubMed ID: 31786671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stop codon context influences genome-wide stimulation of termination codon readthrough by aminoglycosides.
    Wangen JR; Green R
    Elife; 2020 Jan; 9():. PubMed ID: 31971508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutics based on stop codon readthrough.
    Keeling KM; Xue X; Gunn G; Bedwell DM
    Annu Rev Genomics Hum Genet; 2014; 15():371-94. PubMed ID: 24773318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceuticals Promoting Premature Termination Codon Readthrough: Progress in Development.
    Li S; Li J; Shi W; Nie Z; Zhang S; Ma F; Hu J; Chen J; Li P; Xie X
    Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Readthrough strategies for stop codons in Duchenne muscular dystrophy.
    Aurino S; Nigro V
    Acta Myol; 2006 Jun; 25(1):5-12. PubMed ID: 17039975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translational read-through as an alternative approach for ocular gene therapy of retinal dystrophies caused by in-frame nonsense mutations.
    Nagel-Wolfrum K; Möller F; Penner I; Wolfrum U
    Vis Neurosci; 2014 Sep; 31(4-5):309-16. PubMed ID: 24912600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aminoglycosides and other factors promoting stop codon readthrough in human cells.
    Diop D; Chauvin C; Jean-Jean O
    C R Biol; 2007 Jan; 330(1):71-9. PubMed ID: 17241950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Allele-specific therapy: suppression of nonsense mutations by readthrough inducers].
    Floquet C; Rousset JP; Bidou L
    Med Sci (Paris); 2012 Feb; 28(2):193-9. PubMed ID: 22377308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of premature stop codon readthrough in the CFTR gene by Ataluren (PTC124) derivatives.
    Pibiri I; Lentini L; Melfi R; Gallucci G; Pace A; Spinello A; Barone G; Di Leonardo A
    Eur J Med Chem; 2015 Aug; 101():236-44. PubMed ID: 26142488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmaceuticals targeting nonsense mutations in genetic diseases: progress in development.
    Rowe SM; Clancy JP
    BioDrugs; 2009; 23(3):165-74. PubMed ID: 19627168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system.
    Keeling KM; Bedwell DM
    J Mol Med (Berl); 2002 Jun; 80(6):367-76. PubMed ID: 12072912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic and quantitative analysis of stop codon readthrough in Rett syndrome nonsense mutations.
    Lebeda D; Fierenz A; Werfel L; Rosin-Arbesfeld R; Hofhuis J; Thoms S
    J Mol Med (Berl); 2024 May; 102(5):641-653. PubMed ID: 38430393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toward a rationale for the PTC124 (Ataluren) promoted readthrough of premature stop codons: a computational approach and GFP-reporter cell-based assay.
    Lentini L; Melfi R; Di Leonardo A; Spinello A; Barone G; Pace A; Palumbo Piccionello A; Pibiri I
    Mol Pharm; 2014 Mar; 11(3):653-64. PubMed ID: 24483936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mRNA-specific readthrough of nonsense codons by antisense oligonucleotides (R-ASOs).
    Susorov D; Echeverria D; Khvorova A; Korostelev AA
    Nucleic Acids Res; 2024 Aug; 52(15):8687-8701. PubMed ID: 39011883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.